Saturday 17 October 2026
Export CUPR’s income statement to Excel — free account
Cuprina Holdings (Cayman) Limited
CUPR Healthcare Medical Instruments & Supplies
Cuprina Holdings (Cayman) Limited’s revenue for fiscal 2025 (year ended December 2025) was $38,800.00, up 9.30% from fiscal 2024.
1.90
0.05
−2.56%
Follow CUPR
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 3.01 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 76.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 14 | 14 | 10 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 0 | 0 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | (6.20) | (1.29) | |||||
| EBT | — | — | — | — | — | — | — | — | (1) | (4) | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | (3,123.94) | (9,237.11) | |||||
| Net income | — | — | — | — | — | — | — | 0 | (1) | (4) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.02 | 0.02 | ||||
| Earnings | — | — | — | — | — | — | — | — | (0.48) | (1.44) | |||||
| Cash flow | — | — | — | — | — | — | — | — | (0.40) | (2.77) | |||||
| Capex | — | — | — | — | — | — | — | — | (0.01) | (0.02) | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (0.41) | (2.79) | |||||
| Book value | — | — | — | — | — | — | — | — | (1.46) | 1.54 | |||||
| Shares, m | — | — | — | — | — | — | — | — | 2 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (1) | (7) | ||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (1) | (7) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | (3) | 3 | ||||
| Total debt | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Net debt | — | — | — | — | — | — | — | — | 0 | (2) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (3) | 4 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | (178.86) | (92.04) | ||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (130.67) | |||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (1,114.99) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025
Charts ten years each
Cuprina Holdings (Cayman) Limited vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MLSS Milestone Scientific, Inc. | $29.6M | — (loss-making) | — (loss-making) | +22.27% (above 0%: growing) | n/m | +66.68% (above 0%: growing) | 67.24% | (37.37%) | Compare |
| RVP Retractable Technologies, Inc. | $17.6M | — (loss-making) | 11.1× | −31.07% (below 0%: shrinking) | n/m | +56.67% (above 0%: growing) | 2.65% | (71.46%) | Compare |
| BNGO Bionano Genomics, Inc. | $16.1M | — (loss-making) | — (loss-making) | +21.36% (above 0%: growing) | n/m | −33.93% (below 0%: shrinking) | 52.80% | (88.34%) | Compare |
| NXGL NexGel, Inc. | $15.9M | — (loss-making) | — (loss-making) | +27.81% (above 0%: growing) | n/m | −432.32% (below 0%: shrinking) | 30.09% | (67.96%) | Compare |
| FEMY Femasys Inc. | $14.5M | — (loss-making) | — (loss-making) | −18.93% (below 0%: shrinking) | n/m | +11.29% (above 0%: growing) | 57.08% | (1,526.79%) | Compare |
| CUPR Cuprina Holdings (Cayman) Limited | $11.5M | — | — | — | — | — | — | — | |
| RGNT Regentis Biomaterials Ltd. | $10.9M | — | — | — | — | −132.79% (below 0%: shrinking) | — | — | Compare |
| LUCY Innovative Eyewear, Inc. | $7.3M | — (loss-making) | — | +74.46% (above 0%: growing) | n/m | +9.61% (above 0%: growing) | 24.00% | (168.73%) | Compare |
| MHUAF Meihua International Medical Technologies Co., Ltd. | $4.3M | — | — | — | — | −61.55% (below 0%: shrinking) | 35.48% | 0.00% | Compare |
| Median of peers | $15.2M | — | — | +21.82% | — | −12.16% | 35.48% | (71.46%) |
Cuprina Holdings (Cayman) Limited (CUPR) key facts
- Concern: Cuprina Holdings (Cayman) Limited reported a net loss of $3.6 million, or a loss of $1.44 per share, for fiscal 2025.
- Strength: Cuprina Holdings (Cayman) Limited’s revenue for fiscal 2025 (year ended December 2025) was $38,800.00, up 9.30% from fiscal 2024.
- Cuprina Holdings (Cayman) Limited (CUPR) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CUPR traded at $1.90, a market capitalization of $11.5 million.
- Return on equity was −1,115.0% and debt-to-equity 0.07.
- Its Altman Z-score is −0.96 (distress zone) for fiscal 2025.